- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03504241
Tolerance by Engaging Antigen During Cellular Homeostasis (TEACH)
Donor-derived Mesenchymal Stromal Cells, Alemtuzumab, Co-stimulation Blockade and Sirolimus for Tolerance Induction in Adult Kidney Allograft Recipients (ITN062ST)
Anti-rejection medicines, also known as immunosuppressive drugs, are prescribed to organ transplant recipients to prevent rejection of the new organ. Long-term use of these medicines places transplant recipients at higher risk of serious infections and certain types of cancer.
The purpose of this study is to determine if:
- it is safe to give mesenchymal stromal cells (MSCs) to kidney transplant recipients, and
- the combination of the immunosuppressive (anti-rejection) study drugs plus the MSCs can allow a kidney transplant recipient to slowly reduce and/or then completely stop all anti-rejection drugs, without rejection of their kidney (renal) allograft, a process called "immunosuppression withdrawal".
Study Overview
Status
Detailed Description
Background:The most common problem following a kidney transplant is the development of acute or chronic rejection. Rejection is the immunologic reaction in which the body refuses to accept the transplanted organ. The body's immune system will make destructive antibodies that will attempt to attack the transplanted organ.
In order to prevent organ rejection, all patients receiving an allograft (a graft transplanted between genetically non-identical individuals of the same species) must take anti-rejection (immunosuppressive) therapy. These medications function by lowering the body's natural immune system. Often these medications are associated with significant side effects ranging from infections to cancer.
Study:
This is a single center, open label, dose-escalation clinical trial in 6 adult recipients of Human Leukocyte Antigen (HLA)- non-identical, living-donor renal allografts. All participants will receive induction therapy with alemtuzumab followed by maintenance therapy with sirolimus and belatacept.
A total of 2 dosing cohorts of 2 recipients each will receive 12 infusions of donor-derived MSCs starting on Day 42 post-transplant and every 4 weeks starting on Day 56 post-transplant, with a minimum of 7 days between the first and second MSC infusions.
The primary objective is to determine whether immune reconstitution after lymphocyte depletion in the setting of co-stimulatory blockade and systemic MSC-derived donor antigen can promote operational tolerance in recipients of kidney allografts.
Participants will be evaluated for eligibility for sirolimus withdrawal any time between week 52 and week 104 post-transplant. Participants who successfully complete sirolimus withdrawal will remain on belatacept monotherapy for at least 24 weeks before being assessed for eligibility to discontinue belatacept. Participants who successfully complete Immunosuppression Withdrawal (ISW) will then undergo 24 weeks of high frequency follow up followed by 132 weeks of standard follow up.
Study participation may continue for up to seven (7) years after kidney transplant surgery.
*** IMPORTANT NOTICE: *** The National Institute of Allergy and Infectious Diseases and the Immune Tolerance Network do not recommend the discontinuation of immunosuppressive therapy for recipients of cell, organ, or tissue transplants outside of physician-directed, controlled clinical studies. Discontinuation of prescribed immunosuppressive therapy can result in serious health consequences and should only be performed in certain rare circumstances, upon the recommendation and with the guidance of your health care provider.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Health System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Recipient:
Adult candidates of an human leukocyte antigen (HLA)-non-identical, living-donor kidney transplant:
--Candidates must meet the United Network for Organ Sharing (UNOS) criteria, including laboratory criteria, for transplant listing;
- Evidence of established immunity to Epstein-Barr Virus (EBV) as demonstrated by serologic testing;
- Serological evidence of prior Cytomegalovirus (CMV) infection if donor is CMV positive;
For women of child bearing potential:
- A negative serum or urine pregnancy test with sensitivity of less than 50 mIU/mL within 72 hours of start of study medication; and
Agreement to use contraception:
--- According to the FDA Office of Women's Health (http://www.fda.gov/birthcontrol), there are a number of birth control methods that are more than 80% effective
----Female recipients of child-bearing potential must consult with their physician and determine the most suitable method(s) from this list to be used for 18 months after the first dose of study therapy.
Donor:
Meets institutional selection criteria for organ and bone marrow donation:
--All donors will be screened and tested in accordance with:
- (i) FDA 21 CRF 1271.85 requirements for donors of human cells, tissues, and cellular- and tissue-based products (HCT/P); and
- (ii) standards for living kidney donors testing for infection established by the United Network for Organ Sharing (UNOS).
- Ability to understand and provide informed consent for all study procedures including kidney transplant and bone marrow harvest.
Exclusion Criteria:
Recipient:
- History of any immunodeficiency syndrome (including Human Immunodeficiency Virus-1 (HIV-1) and HIV-2);
- Positive anti-Hepatitis C Virus (HCV) Polymerase Chain Reaction (PCR), anti-Hepatitis C Virus (HBV) PCR, or HBV surface antigen;
- History of malignancy within 5 years of enrollment or any history of hematogenous malignancy or lymphoma; --Exception: Participants with curatively treated non-melanomatous skin cancer or curatively treated cervical carcinoma in situ may be enrolled.
Underlying renal disease with high likelihood of recurrence, including but not limited to:
- primary focal segmental glomerulosclerosis (FSGS),
- Type I or II membranoproliferative glomerulonephritis (MPGN),
- hemolytic-uremic syndrome and
- thrombotic thrombocytopenic purpura (HUS/TTP) syndrome. ---Subject(s) with end-stage renal disease (ESRD) of unknown etiology and/or has no histologically confirmed diagnosis, may be enrolled into the study as long as there are no clinical signs or symptoms consistent with excluded clinical diagnoses.
History of active M. tuberculosis:
--Participants with a history of latent M. tuberculosis (LTB) as defined by positive testing for tuberculosis using an approved IGRA blood test, such as QuantiFERON®-Gold TB or T-SPOT-TB assay must:
- have completed treatment for LTB and
- have a negative chest x-ray. ----All participants will undergo IGRA testing for M tuberculosis within 3 months prior to transplant.
- Current or historical evidence of donor-specific antibody;
- Immunosuppressive drug therapy within one year prior to enrollment.
- May not be taking or have taken prednisone, cyclosporine A, tacrolimus, azathioprine, Mycophenolate Mofetil (MMF), cyclophosphamide, methotrexate, infliximab, etanercept, or other agents which have a primary therapeutic effect of immunosuppression in the year prior to transplantation.
May not have taken depletional anti-lymphocyte agents at any time.
---Exceptions:
- Short (≤ 30 days) courses of topical or inhaled steroids are permitted, as are
- Short oral or parental pulses for a documented hypersensitivity reaction.
- Active autoimmune disease requiring ongoing immunosuppressive therapy or other conditions in which there is an anticipated need for immunosuppressive maintenance therapy;
- Uncompensated congestive heart failure, pulmonary edema, or symptomatic pulmonary hypertension;
- Active severe infection within a month of the screening visit;
- Use of an investigational drug within 30 days of the screening visit;
- Presence of any medical condition that the investigator deems incompatible with trial participation; or
- Inability or unwillingness to comply with protocol monitoring and therapy.
Donor:
- History of blood donation to the recipient;
- Evidence of prior Cytomegalovirus (CMV) infection if the recipient is CMV negative;
- History of HIV-1/HIV-2 infection;
- Positive HCV PCR, HBV PCR or HBV surface antigen;or
- Presence of any medical condition that the investigator deems incompatible with trial participation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MSCs 10^4 cells/kg+anti-rejection drugs
The first dosing cohort of 2 participants will receive 12 infusions of 10^4 donor-derived Mesenchymal Stromal Cells (MSCs) cells/kg every 4-weeks.
|
These MSCs are a cellular product derived from bone marrow and propagated ex vivo using FDA-approved, clinically applicable methods.
Their use in kidney transplantation has been associated with a good safety profile.
Other Names:
Alemtuzumab, 30 mg, given once intravenously (IV) over three hours.
The infusion of alemtuzumab shall begin within 24 hours of transplantation surgery and shall be given prior to the first dose of belatacept.
Other Names:
Belatacept will be given as an intravenous (IV) infusion of 10mg /kg over 1 hour on transplantation postoperative Day 0, Days 5 and 14, then every 2 weeks (± 2 days) for 5 additional doses.Thereafter, belatacept will be given once every 4 weeks (± 5 days) at 10 mg/kg through 24 weeks post-transplant, then at 5 mg/kg every 4-weeks until the participant is evaluated for belatacept discontinuation.
Other Names:
Rapamune® (sirolimus) (Wyeth Pharmaceuticals Inc., Philadelphia, PA) will be started on transplantation postoperative day 1 at a dose of 2 mg/day orally and adjusted to maintain goal 24-hour trough levels of 8-10 ng/ml.
Participants who experience grade 3 sirolimus toxicity will undergo dose reduction.
Other Names:
Per protocol, and, only permitted in cases of sirolimus intolerance.
Other Names:
Per protocol, and, only permitted in cases of sirolimus intolerance.
Other Names:
Per protocol, and, only permitted in cases of sirolimus intolerance.
Other Names:
|
Experimental: MSCs 10^5 cells/kg+anti-rejection drugs
If the first 3 infusions of 10^4 donor-derived Mesenchymal Stromal Cells (MSCs) cells/kg are well tolerated, this cohort of 2 participants will receive 12 infusions of 10^5 cells/kg every 4-weeks.
|
These MSCs are a cellular product derived from bone marrow and propagated ex vivo using FDA-approved, clinically applicable methods.
Their use in kidney transplantation has been associated with a good safety profile.
Other Names:
Alemtuzumab, 30 mg, given once intravenously (IV) over three hours.
The infusion of alemtuzumab shall begin within 24 hours of transplantation surgery and shall be given prior to the first dose of belatacept.
Other Names:
Belatacept will be given as an intravenous (IV) infusion of 10mg /kg over 1 hour on transplantation postoperative Day 0, Days 5 and 14, then every 2 weeks (± 2 days) for 5 additional doses.Thereafter, belatacept will be given once every 4 weeks (± 5 days) at 10 mg/kg through 24 weeks post-transplant, then at 5 mg/kg every 4-weeks until the participant is evaluated for belatacept discontinuation.
Other Names:
Rapamune® (sirolimus) (Wyeth Pharmaceuticals Inc., Philadelphia, PA) will be started on transplantation postoperative day 1 at a dose of 2 mg/day orally and adjusted to maintain goal 24-hour trough levels of 8-10 ng/ml.
Participants who experience grade 3 sirolimus toxicity will undergo dose reduction.
Other Names:
Per protocol, and, only permitted in cases of sirolimus intolerance.
Other Names:
Per protocol, and, only permitted in cases of sirolimus intolerance.
Other Names:
Per protocol, and, only permitted in cases of sirolimus intolerance.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Participants who Achieve Operational Tolerance
Time Frame: 52 weeks after completion of Immunosuppression Withdrawal (ISW)
|
Operational tolerance (to their kidney transplant) defined by participant remaining off all immunosuppression for 52 weeks after completion of Immunosuppression Withdrawal (ISW) with:
|
52 weeks after completion of Immunosuppression Withdrawal (ISW)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Participants who Remain Off Immunosuppression
Time Frame: From ISW completion to end of study participation (up to approximately 5 years)
|
For the duration of their study participation, after completion of immunosuppression withdrawal (ISW).
|
From ISW completion to end of study participation (up to approximately 5 years)
|
Proportion of Participants who Return to Immunosuppression
Time Frame: From ISW completion to end of study participation (up to approximately 5 years)
|
Resumption of immunosuppressive therapy post completion of Immunosuppression Withdrawal (ISW), per standard of care.
|
From ISW completion to end of study participation (up to approximately 5 years)
|
Proportion of Participants who Achieve Belatacept Monotherapy
Time Frame: 48 weeks from the time of last sirolimus dose
|
Belatacept monotherapy, defined as remaining on belatacept as the sole maintenance regimen for 48 weeks with:
|
48 weeks from the time of last sirolimus dose
|
Proportion of Participants who Die
Time Frame: From kidney transplant with alemtuzumab induction to to completion of study (up to approximately 6.5 years)
|
This analysis will include all participants who provide informed consent for study participation and receive any form of study therapy including alemtuzumab, sirolimus, belatacept, or MSC infusions.
|
From kidney transplant with alemtuzumab induction to to completion of study (up to approximately 6.5 years)
|
Time from Transplant to the First Episode of Rejection
Time Frame: From kidney transplantation to completion of study (up to approximately 7 years)
|
Kaplan-Meier Analysis of time-to-occurrence to the first episode of kidney allograft rejection.
|
From kidney transplantation to completion of study (up to approximately 7 years)
|
Incidence of Participants who Develop Donor Specific Antibody (DSA)
Time Frame: From study enrollment to completion of study (up to approximately 7 years)
|
Participants that Develop de novo Anti-Human Leukocyte Antigen (HLA) Antibody or Donor Specific Antibodies (DSA).
|
From study enrollment to completion of study (up to approximately 7 years)
|
Incidence of Adverse Events Attributable to Mesenchymal Stromal Cells (MSC) Administration
Time Frame: From initial MCS infusion (day 42 post kidney transplant) to end of study participation (up to 7 years)
|
According to medical assessment/outcomes, investigator's brochure for MSCs, literature et al.
|
From initial MCS infusion (day 42 post kidney transplant) to end of study participation (up to 7 years)
|
Frequency of Select Adverse Events (AEs)
Time Frame: From kidney transplantation to completion of study (up to approximately 7 years)
|
Select AEs include:
|
From kidney transplantation to completion of study (up to approximately 7 years)
|
Incidence of Post-Transplant Diabetes
Time Frame: From post kidney transplantation to completion of study (up to approximately 7 years)
|
New onset diabetes status post transplant (posttransplantation diabetes mellitus [PTDM])
|
From post kidney transplantation to completion of study (up to approximately 7 years)
|
Frequency of Antibody-Mediated Acute Cellular Rejection
Time Frame: From kidney transplant to completion of study (up to approximately 7 years)
|
Using the 2017 Banff Classification of Renal Allograft Pathology.
|
From kidney transplant to completion of study (up to approximately 7 years)
|
Frequency of Antibody-Mediated Chronic Rejection
Time Frame: From kidney transplant to completion of study (up to approximately 7 years)
|
Using the 2017 Banff Classification of Renal Allograft Pathology. As measured by the incidence of biopsy-proven chronic allograft nephropathy/IF/TA |
From kidney transplant to completion of study (up to approximately 7 years)
|
Collaborators and Investigators
Investigators
- Study Chair: Allan D. Kirk, M.D., Ph.D., Duke University Medical Center: Transplantation
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Immunological
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Immune Checkpoint Inhibitors
- Antitubercular Agents
- Antibiotics, Antitubercular
- Prednisone
- Mycophenolic Acid
- Sirolimus
- Abatacept
- Alemtuzumab
Other Study ID Numbers
- DAIT ITN062ST
- UM1AI109565 (U.S. NIH Grant/Contract)
- NIAID CRMS ID#: 20676 (Other Identifier: DAIT NIAID)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Transplantation
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedKidney Transplantation | Renal Transplantation | Transplantation, Kidney | Grafting, Kidney | Transplantation, RenalBelgium, Germany, Spain, Sweden, Italy, Switzerland, United Kingdom, Austria, France, Poland, Czech Republic, Netherlands
-
Bristol-Myers SquibbCompletedKidney Transplantation: Transplantation, Kidney
-
Nantes University HospitalTerminated
-
Hospices Civils de LyonCompletedKidney Transplantation | Pancreas-kidney TransplantationFrance
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCzechia, France, Italy, Poland, United Kingdom
-
The Hospital for Sick ChildrenCompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCanada
-
Astellas Pharma Europe Ltd.TerminatedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationSpain, Australia, France, Germany, Canada, Italy, United Kingdom, Belgium, South Africa, Switzerland, Sweden, United States, Austria, Brazil, Czechia, Denmark, Finland, Hungary, Ireland, Mexico, Netherlands, New Zealand, Poland
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Medical University of ViennaUnknownKidney Function After Transplantation | Outcome After Kidney Transplantation
Clinical Trials on Donor-derived Mesenchymal Stromal Cells
-
Leiden University Medical CenterCompletedRejection | Graft LossNetherlands
-
American CryoStem CorporationTerminatedMultiple SclerosisCayman Islands
-
Mayo ClinicState of Minnesota Regenerative Medicine MinnesotaActive, not recruitingAmyotrophic Lateral Sclerosis | ALSUnited States
-
Universidad de los Andes, ChileUnknownOsteoarthritis, KneeChile
-
Leiden University Medical CenterUnknownFibrosis | Renal Transplant RejectionNetherlands
-
Mayo ClinicRegenerative Medicine MinnesotaTerminatedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Diabetic Kidney Disease | Diabetic Nephropathies | Chronic Kidney Disease | Kidney Failure | Diabetic Nephropathy Type 2 | Kidney InsufficiencyUnited States
-
Rigshospitalet, DenmarkCompletedChronic Ischemic Heart DiseaseDenmark
-
Guangzhou General Hospital of Guangzhou Military...UnknownParkinson's DiseaseChina
-
Guangzhou General Hospital of Guangzhou Military...UnknownSpinal Cord InjuryChina
-
Guangzhou General Hospital of Guangzhou Military...Guangzhou Municipal Twelfth People's Hospital; Guangdong Prevention and Treatment...Unknown